Nebivolol-induced gynecomastia.

Area of Science:

• Pharmacology
• Endocrinology
• Cardiology

Background:

• Adverse drug reactions are a known cause of gynecomastia.
• Cardiovascular drugs have been previously linked to gynecomastia.
• Nebivolol, a third-generation beta-blocker, has not been previously associated with gynecomastia.

Observation:

• A 42-year-old male presented with bilateral gynecomastia.
• Gynecomastia developed after the initiation of nebivolol therapy.
• Other potential causes of gynecomastia were ruled out.

Findings:

• Nebivolol use was associated with the development of bilateral gynecomastia.
• Discontinuation of nebivolol led to the complete regression of gynecomastia.
• This represents the first reported case of nebivolol-induced gynecomastia.

Implications:

• Nebivolol should be considered a potential cause of drug-induced gynecomastia.
• Discontinuation of the offending medication is an effective treatment strategy.
• Further research may be warranted to explore the mechanism of nebivolol-induced gynecomastia.